• Explore /
  • Poster
  • / A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellite-stable, refractory, metastatic colorectal cancer (mCRC).

A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellite-stable, refractory, metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Tyler Friedrich

University of Colorado Comprehensive Cancer Center, Aurora, CO

Tyler Friedrich , Patrick Jud Blatchford , Robert William Lentz , S. Lindsey Davis , Sunnie S. Kim , Alexis Diane Leal , Zoe Van De Voorde , Matthew R Lee , Meredith Waring , Tiffany Cull , Anne Martin , S. Gail Eckhardt , Wells A. Messersmith , Christopher Hanyoung Lieu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03475004

DOI

10.1200/JCO.2022.40.4_suppl.118

Abstract #

118

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Christopher Hanyoung Lieu

First Author: Daisuke Kotani

First Author: Andrea Grace Bocobo

First Author: Hideaki Bando